Rapport Therapeutics, Inc. Stock 12‑Month Price Target Cut to $68.29, Implies 173% Upside

What happened

Rapport Therapeutics' average 12-month price target from 14 analysts fell from $69 to $68.29, with forecasts ranging from $50 to $91 per share. Based on the October 30 closing price, the new target implies about 173% potential upside, and the consensus rating remains Buy across 16 analysts.

Confirmed

Global impact / market context

Analysts still expect the stock to roughly double, so the small cut suggests confidence is broadly intact rather than shaken. Because forecasts range widely from $50 to $91, investors disagree about the company's prospects, meaning future results could move the shares sharply.

Analyst inference

A near-173% implied upside means the current share price sits far below what analysts think the business is worth, which often happens when a stock is out of favor or viewed as risky. All 16 analysts rating it Buy signals one-sided positive positioning.

Analyst inference

What to watch

1. Watch whether the average target keeps slipping from $68.29, since a steady decline could signal analysts growing less confident even while their overall Buy rating stays in place. Confirmed
2. Track whether any analyst changes their rating from Buy, because losing even one Buy would break the current 16-to-zero consensus and could shift how investors view the stock. Proposed
3. Compare future company results against analyst forecasts, since the wide $50 to $91 target range suggests estimates are uncertain and surprises could pull targets toward either end. Analyst inference

Evidence

• Original source link unavailable